Small study showed high accuracy but hurdles remain, two experts said
by Mike_in_Co on Thu Nov 18, 2010 09:12 PM
I thought this might benefit some people:
The American Society of Clinical Oncology recently published its Clinical Cancer Advances 2010 and hailed a new drug combination, FOLFIRINOX as being the most significant advance for pancreatic cancer this year.
The study’s authors, presenting at ASCO 2010, reported 48% of patients on FOLFIRINOX were alive after 1 year compared to 20% on the gemcitabine arm and, for the first time in a study involving patients with metastatic pancreatic cancer, a median overall survival of 11.1 months was obtained on the FOLFIRINOX arm.
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
We care about your feedback. Let us know how we can improve your CancerCompass experience.